Relay Therapeutics Inc. Common Stock (RLAY)

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

202

Website

relaytx.com/

Fundamentals

1-day range

$18.63$19.3

Market cap

$3.60B

P/E (trailing)

—

P/E (forward)

-11.42

EPS (trailing)

$-1.57

Dividend yield

—

Beta

1.70

Avg. volume

3.33M

Forecasts

13 analyst ratings

Relay Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.60BP/E —
  $3.5$21.27
• ADPT

  Adaptive Biotechnologies Corporation Common Stock

  $25.19

  ▼ 4.73%
  Market cap $3.70BP/E —
  $12$26.87
• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.67BP/E —
  $16.02$38.26
• KOD

  Kodiak Sciences Inc Common Stock

  $37.77

  ▼ 3.45%
  Market cap $2.49BP/E —
  $8.29$47.84
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.78BP/E —
  $44.12$78.48
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.10BP/E —
  $23$55.42
• MESO

  Mesoblast Limited American Depositary Shares

  $17.42

  ▼ 4.18%
  Market cap $1.87BP/E —
  $1.88$3.31

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29
  benzinga · 8/20/2026
• HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29
  Benzinga · 8/20/2026
• JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31
  Benzinga · 8/14/2026
• Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
  SeekingAlpha · 8/10/2026
• Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26
  Benzinga · 8/10/2026
• Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30
  Benzinga · 8/7/2026
• Relay Therapeutics (NASDAQ:RLAY) Reports Q2 2026 Revenue Miss as Loss Widens Slightly
  ChartMill · 8/7/2026
• Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate
  Benzinga · 8/6/2026

• Catinazzo Thomas · July 28, 2026 · Sale

  1.5K @ $18.61
• Rahmer Peter · July 28, 2026 · Sale

  748 @ $18.61
• Bergstrom Donald A · July 28, 2026 · Sale

  2.2K @ $18.61
• Patel Sanjiv · July 7, 2026 · Sale

  48.2K @ $19.58
• Catinazzo Thomas · July 6, 2026 · Sale

  17.7K @ $18.69
• Bergstrom Donald A · July 6, 2026 · Sale

  8.7K @ $18.71
• Patel Sanjiv · June 30, 2026 · Grant

  3.1K @ $6.95
• Rahmer Peter · June 30, 2026 · Grant

  3.1K @ $6.95
• Rahmer Peter · June 30, 2026 · Sale

  50.0K @ $19.09
• Catinazzo Thomas · June 22, 2026 · Option Exercise

  51.6K @ $4.45
• Catinazzo Thomas · June 22, 2026 · Option Exercise

  61.6K @ $5.22
• Catinazzo Thomas · June 22, 2026 · Option Exercise

  56.3K @ $5.04
• Catinazzo Thomas · June 22, 2026 · Sale

  51.6K @ $16.97
• Catinazzo Thomas · June 22, 2026 · Sale

  61.6K @ $16.97
• Catinazzo Thomas · June 22, 2026 · Sale

  56.3K @ $16.97

Institutional Ownership

March 31, 2026

Total shares held

181.35M

Total value held

$1.77B

Institutional holders

235